Abiraterone
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Abiraterone resulting in a loss in efficacy.
Acenocoumarol
Tamoxifen may increase the anticoagulant activities of Acenocoumarol.
Acetaminophen
The metabolism of Acetaminophen can be decreased when combined with Tamoxifen.
Advertisement
Acetyl salicylate
The metabolism of Acetylsalicylic acid can be decreased when combined with Tamoxifen.
Acetyl Sulfisoxazole
The metabolism of Tamoxifen can be decreased when combined with Acetyl sulfisoxazole.
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Tamoxifen.
Advertisement
Afatinib
The serum concentration of Afatinib can be decreased when it is combined with Tamoxifen.
Almotriptan
The metabolism of Almotriptan can be decreased when combined with Tamoxifen.
Aminopyrine
The metabolism of Aminophenazone can be decreased when combined with Tamoxifen.
Advertisement
Amiodarone
The serum concentration of Tamoxifen can be increased when it is combined with Amiodarone.
Amitriptyline
The metabolism of Amitriptyline can be decreased when combined with Tamoxifen.
Amodiaquine
The serum concentration of Amodiaquine can be increased when it is combined with Tamoxifen.
Amprenavir
The metabolism of Amprenavir can be decreased when combined with Tamoxifen.
Anagrelide
Tamoxifen may increase the QTc-prolonging activities of Anagrelide.
Anastrozole
The serum concentration of Anastrozole can be decreased when it is combined with Tamoxifen.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Tamoxifen.
Antipyrine
The metabolism of Antipyrine can be decreased when combined with Tamoxifen.
Apalutamide
The serum concentration of Tamoxifen can be decreased when it is combined with Apalutamide.
Apixaban
The metabolism of Apixaban can be decreased when combined with Tamoxifen.
Aprepitant
The serum concentration of Tamoxifen can be increased when it is combined with Aprepitant.
Aripiprazole
The serum concentration of Aripiprazole can be decreased when it is combined with Tamoxifen.
Armodafinil
The metabolism of Tamoxifen can be decreased when combined with Armodafinil.
Arsenic Trioxide
Tamoxifen may increase the QTc-prolonging activities of Arsenic trioxide.
Artemether
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Artemether resulting in a loss in efficacy.
Asenapine
Tamoxifen may increase the QTc-prolonging activities of Asenapine.
Aspirin
The metabolism of Acetylsalicylic acid can be decreased when combined with Tamoxifen.
Asunaprevir
The serum concentration of Asunaprevir can be decreased when it is combined with Tamoxifen.
Atazanavir
The metabolism of Tamoxifen can be decreased when combined with Atazanavir.
Atomoxetine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Atomoxetine resulting in a loss in efficacy.
Atorvastatin
The risk or severity of adverse effects can be increased when Tamoxifen is combined with Atorvastatin.
Azelastine
The metabolism of Azelastine can be decreased when combined with Tamoxifen.
Azithromycin
The metabolism of Tamoxifen can be decreased when combined with Azithromycin.
Bedaquiline
Tamoxifen may increase the QTc-prolonging activities of Bedaquiline.
Benzyl Alcohol
The metabolism of Benzyl alcohol can be decreased when combined with Tamoxifen.
Betaxolol
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Betaxolol resulting in a loss in efficacy.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Tamoxifen.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Tamoxifen.
Bexarotene
The serum concentration of Tamoxifen can be decreased when it is combined with Bexarotene.
Bioallethrin
The metabolism of Bioallethrin can be decreased when combined with Tamoxifen.
Boceprevir
The metabolism of Tamoxifen can be decreased when combined with Boceprevir.
Bortezomib
The metabolism of Tamoxifen can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Tamoxifen can be decreased when it is combined with Bosentan.
Bosentan Anhydrous
The serum concentration of Tamoxifen can be decreased when it is combined with Bosentan.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Tamoxifen.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Tamoxifen.
Brentuximab Vedotin
The serum concentration of Brentuximab vedotin can be decreased when it is combined with Tamoxifen.
Brigatinib
The metabolism of Brigatinib can be decreased when combined with Tamoxifen.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Tamoxifen.
Brompheniramine
The metabolism of Brompheniramine can be decreased when combined with Tamoxifen.
Buprenorphine
The metabolism of Buprenorphine can be decreased when combined with Tamoxifen.
Bupropion
The serum concentration of Tamoxifen can be increased when it is combined with Bupropion.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tamoxifen.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Tamoxifen.
Caffeine
The metabolism of Tamoxifen can be decreased when combined with Caffeine.
Capecitabine
The metabolism of Tamoxifen can be decreased when combined with Capecitabine.
Carbamazepine
The metabolism of Tamoxifen can be increased when combined with Carbamazepine.
Carbinoxamine
The metabolism of Carbinoxamine can be decreased when combined with Tamoxifen.
Celecoxib
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Celecoxib resulting in a loss in efficacy.
Ceritinib
The serum concentration of Tamoxifen can be increased when it is combined with Ceritinib.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Tamoxifen.
Chloramphenicol
The metabolism of Tamoxifen can be decreased when combined with Chloramphenicol.
Chloroquine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Chloroquine resulting in a loss in efficacy.
Chlorpromazine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Chlorpromazine resulting in a loss in efficacy.
Cholecalciferol
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Cholecalciferol resulting in a loss in efficacy.
Cholic Acid
Tamoxifen may decrease the excretion rate of Cholic Acid which could result in a higher serum level.
Cimetidine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Cimetidine resulting in a loss in efficacy.
Cinacalcet
The serum concentration of Tamoxifen can be increased when it is combined with Cinacalcet.
Ciprofloxacin
Tamoxifen may increase the QTc-prolonging activities of Ciprofloxacin.
Cisapride
Tamoxifen may increase the QTc-prolonging activities of Cisapride.
Citalopram
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Citalopram resulting in a loss in efficacy.
Clarithromycin
The metabolism of Tamoxifen can be decreased when combined with Clarithromycin.
Clemastine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Clemastine resulting in a loss in efficacy.
Clobazam
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Clobazam resulting in a loss in efficacy.
Clomipramine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Clomipramine resulting in a loss in efficacy.
Clopidogrel
The metabolism of Tamoxifen can be decreased when combined with Clopidogrel.
Clotrimazole
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Clotrimazole resulting in a loss in efficacy.
Clozapine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Clozapine resulting in a loss in efficacy.
Cobicistat
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Cobicistat resulting in a loss in efficacy.
Cocaine
The serum concentration of Tamoxifen can be increased when it is combined with Cocaine.
Colchicine
The serum concentration of Colchicine can be increased when it is combined with Tamoxifen.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Tamoxifen.
Crisaborole
The metabolism of Tamoxifen can be decreased when combined with Crisaborole.
Crizotinib
The metabolism of Tamoxifen can be decreased when combined with Crizotinib.
Curcumin
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Curcumin resulting in a loss in efficacy.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Tamoxifen.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Tamoxifen.
Cyclosporine
The metabolism of Tamoxifen can be decreased when combined with Cyclosporine.
Cyproterone Acetate
The serum concentration of Tamoxifen can be decreased when it is combined with Cyproterone acetate.
Dabigatran Etexilate
The serum concentration of Dabigatran etexilate can be decreased when it is combined with Tamoxifen.
Dabrafenib
The serum concentration of Tamoxifen can be decreased when it is combined with Dabrafenib.
Dapsone
The metabolism of Dapsone can be decreased when combined with Tamoxifen.
Darifenacin
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Darifenacin resulting in a loss in efficacy.
Darunavir
The serum concentration of Tamoxifen can be increased when it is combined with Darunavir.
Dasabuvir
The metabolism of Dasabuvir can be decreased when combined with Tamoxifen.
Dasatinib
The serum concentration of Tamoxifen can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Tamoxifen can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Tamoxifen can be decreased when it is combined with Deferasirox.
Delavirdine
The serum concentration of Tamoxifen can be increased when it is combined with Delavirdine.
Desipramine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Desipramine resulting in a loss in efficacy.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Tamoxifen.
Dextromethorphan
The metabolism of Dextromethorphan can be decreased when combined with Tamoxifen.
Diazepam
The metabolism of Diazepam can be decreased when combined with Tamoxifen.
Diclofenac
The metabolism of Diclofenac can be decreased when combined with Tamoxifen.
Dicumarol
Tamoxifen may increase the anticoagulant activities of Dicoumarol.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Tamoxifen.
Digoxin
Digoxin may decrease the cardiotoxic activities of Tamoxifen.
Dihydroergocornine
The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Tamoxifen.
Dihydroergocristine
The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Tamoxifen.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tamoxifen.
Diltiazem
The metabolism of Tamoxifen can be decreased when combined with Diltiazem.
Diphenhydramine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Diphenhydramine resulting in a loss in efficacy.
Disopyramide
Tamoxifen may increase the QTc-prolonging activities of Disopyramide.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Tamoxifen.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Tamoxifen.
Dofetilide
Tamoxifen may increase the QTc-prolonging activities of Dofetilide.
Dolasetron
Tamoxifen may increase the QTc-prolonging activities of Dolasetron.
Domperidone
Tamoxifen may increase the QTc-prolonging activities of Domperidone.
Dothiepin
The serum concentration of Tamoxifen can be increased when it is combined with Dosulepin.
Doxorubicin
The serum concentration of Doxorubicin can be increased when it is combined with Tamoxifen.
Doxorubicin Hydrochloride
The serum concentration of Doxorubicin can be increased when it is combined with Tamoxifen.
Doxycycline
The metabolism of Tamoxifen can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Tamoxifen can be decreased when combined with Doxycycline.
Dronedarone
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Dronedarone resulting in a loss in efficacy.
Droperidol
Tamoxifen may increase the QTc-prolonging activities of Droperidol.
Duloxetine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Duloxetine resulting in a loss in efficacy.
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Tamoxifen.
Efavirenz
The metabolism of Tamoxifen can be decreased when combined with Efavirenz.
Eliglustat
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Eliglustat resulting in a loss in efficacy.
Eltrombopag
The serum concentration of Tamoxifen can be increased when it is combined with Eltrombopag.
Enasidenib
The metabolism of Enasidenib can be decreased when combined with Tamoxifen.
Enzalutamide
The serum concentration of Tamoxifen can be decreased when it is combined with Enzalutamide.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Tamoxifen.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Tamoxifen.
Erlotinib
The metabolism of Erlotinib can be decreased when combined with Tamoxifen.
Erythromycin
The metabolism of Tamoxifen can be decreased when combined with Erythromycin.
Escitalopram
Tamoxifen may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine Acetate
The metabolism of Tamoxifen can be decreased when combined with Eslicarbazepine acetate.
Esomeprazole
The metabolism of Tamoxifen can be decreased when combined with Esomeprazole.
Estradiol
The metabolism of Estradiol can be decreased when combined with Tamoxifen.
Estradiol 3-Benzoate
The metabolism of Estradiol benzoate can be decreased when combined with Tamoxifen.
Estradiol acetate
The metabolism of Estradiol acetate can be decreased when combined with Tamoxifen.
Estradiol Cypionate
The metabolism of Estradiol cypionate can be decreased when combined with Tamoxifen.
Estradiol Valerate
The metabolism of Estradiol valerate can be decreased when combined with Tamoxifen.
Eszopiclone
The metabolism of Eszopiclone can be decreased when combined with Tamoxifen.
Etravirine
The metabolism of Tamoxifen can be decreased when combined with Etravirine.
Everolimus
The serum concentration of Everolimus can be increased when it is combined with Tamoxifen.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tamoxifen.
Flecainide
Tamoxifen may increase the QTc-prolonging activities of Flecainide.
Floxuridine
The metabolism of Tamoxifen can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Tamoxifen can be decreased when combined with Fluconazole.
Fluindione
Tamoxifen may increase the anticoagulant activities of Fluindione.
Fluorouracil
The metabolism of Tamoxifen can be decreased when combined with Fluorouracil.
Fluoxetine
The serum concentration of Tamoxifen can be increased when it is combined with Fluoxetine.
Flupenthixol
Tamoxifen may increase the QTc-prolonging activities of Flupentixol.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Tamoxifen.
Fluvoxamine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Fluvoxamine resulting in a loss in efficacy.
Fosamprenavir
The metabolism of Tamoxifen can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Tamoxifen can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The metabolism of Tamoxifen can be increased when combined with Fosphenytoin.
Fusidate
The serum concentration of Tamoxifen can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Tamoxifen can be increased when it is combined with Fusidic Acid.
Gadobenate
Tamoxifen may increase the QTc-prolonging activities of Gadobenic acid.
Gemfibrozil
The metabolism of Tamoxifen can be decreased when combined with Gemfibrozil.
Gemifloxacin
Tamoxifen may increase the QTc-prolonging activities of Gemifloxacin.
Gemifloxacin Mesylate
Tamoxifen may increase the QTc-prolonging activities of Gemifloxacin.
Goserelin
Tamoxifen may increase the QTc-prolonging activities of Goserelin.
Granisetron
Tamoxifen may increase the QTc-prolonging activities of Granisetron.
Halofantrine
The metabolism of Halofantrine can be decreased when combined with Tamoxifen.
Haloperidol
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Haloperidol resulting in a loss in efficacy.
Hypoxis hemerocallidea root extract
The serum concentration of Tamoxifen can be decreased when it is combined with St. John's Wort.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Tamoxifen.
Ibuprofen
The metabolism of Ibuprofen can be decreased when combined with Tamoxifen.
Ibutilide
Tamoxifen may increase the QTc-prolonging activities of Ibutilide.
Idelalisib
The metabolism of Tamoxifen can be decreased when combined with Idelalisib.
Ifosfamide
The metabolism of Ifosfamide can be decreased when combined with Tamoxifen.
Iloperidone
Tamoxifen may increase the QTc-prolonging activities of Iloperidone.
Imatinib
The metabolism of Tamoxifen can be decreased when combined with Imatinib.
Imipramine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Imipramine resulting in a loss in efficacy.
Indinavir
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Indinavir resulting in a loss in efficacy.
INDINAVIR ANHYDROUS
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Indinavir resulting in a loss in efficacy.
Irbesartan
The metabolism of Tamoxifen can be decreased when combined with Irbesartan.
Isavuconazole
The serum concentration of Tamoxifen can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Tamoxifen can be decreased when combined with Isavuconazonium.
Isoniazid
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Isoniazid resulting in a loss in efficacy.
Isradipine
The metabolism of Tamoxifen can be decreased when combined with Isradipine.
Itraconazole
The metabolism of Tamoxifen can be decreased when combined with Itraconazole.
Ivacaftor
The serum concentration of Tamoxifen can be increased when it is combined with Ivacaftor.
Ixazomib
The metabolism of Ixazomib can be decreased when combined with Tamoxifen.
Ketamine
The metabolism of Ketamine can be decreased when combined with Tamoxifen.
Ketoconazole
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ketoconazole resulting in a loss in efficacy.
Lansoprazole
The metabolism of Lansoprazole can be decreased when combined with Tamoxifen.
Lapatinib
The metabolism of Lapatinib can be decreased when combined with Tamoxifen.
Ledipasvir
The serum concentration of Ledipasvir can be decreased when it is combined with Tamoxifen.
Leflunomide
The metabolism of Tamoxifen can be decreased when combined with Leflunomide.
Lenvatinib
Tamoxifen may increase the QTc-prolonging activities of Lenvatinib.
Lenvatinib Mesylate
Tamoxifen may increase the QTc-prolonging activities of Lenvatinib.
Letrozole
The serum concentration of Letrozole can be decreased when it is combined with Tamoxifen.
Leuprolide
Tamoxifen may increase the QTc-prolonging activities of Leuprolide.
Levofloxacin
Tamoxifen may increase the QTc-prolonging activities of Levofloxacin.
Levofloxacin Anhydrous
Tamoxifen may increase the QTc-prolonging activities of Levofloxacin.
Levomilnacipran
The metabolism of Levomilnacipran can be decreased when combined with Tamoxifen.
Lidocaine
The metabolism of Tamoxifen can be decreased when combined with Lidocaine.
Linagliptin
The serum concentration of Linagliptin can be decreased when it is combined with Tamoxifen.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Tamoxifen.
Loperamide
The metabolism of Loperamide can be decreased when combined with Tamoxifen.
Lopinavir
The serum concentration of Tamoxifen can be increased when it is combined with Lopinavir.
Loratadine
The metabolism of Loratadine can be decreased when combined with Tamoxifen.
Lorcaserin
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Lorcaserin resulting in a loss in efficacy.
Losartan
The metabolism of Tamoxifen can be decreased when combined with Losartan.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Tamoxifen.
Luliconazole
The serum concentration of Tamoxifen can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Tamoxifen can be decreased when it is combined with Lumacaftor.
Lumefantrine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Lumefantrine resulting in a loss in efficacy.
Manidipine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Manidipine resulting in a loss in efficacy.
Mefenamic Acid
The metabolism of Mefenamic acid can be decreased when combined with Tamoxifen.
Meloxicam
The metabolism of Meloxicam can be decreased when combined with Tamoxifen.
Mephenytoin
The metabolism of Mephenytoin can be decreased when combined with Tamoxifen.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Tamoxifen.
Methadone
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Methadone resulting in a loss in efficacy.
Methotrimeprazine
The serum concentration of Tamoxifen can be increased when it is combined with Methotrimeprazine.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tamoxifen.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Tamoxifen.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Tamoxifen.
Mexiletine
The metabolism of Tamoxifen can be decreased when combined with Mexiletine.
Midostaurin
The serum concentration of Tamoxifen can be increased when it is combined with Midostaurin.
Mifepristone
The serum concentration of Tamoxifen can be increased when it is combined with Mifepristone.
Mipomersen
Tamoxifen may increase the hepatotoxic activities of Mipomersen.
Mirabegron
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Mirabegron resulting in a loss in efficacy.
Mirtazapine
The metabolism of Mirtazapine can be decreased when combined with Tamoxifen.
Mitotane
The serum concentration of Tamoxifen can be decreased when it is combined with Mitotane.
Moclobemide
The metabolism of Tamoxifen can be decreased when combined with Moclobemide.
Modafinil
The metabolism of Tamoxifen can be decreased when combined with Modafinil.
Morphine
The metabolism of Morphine can be decreased when combined with Tamoxifen.
Moxifloxacin
Tamoxifen may increase the QTc-prolonging activities of Moxifloxacin.
Mycophenolate Mofetil
The metabolism of Mycophenolate mofetil can be decreased when combined with Tamoxifen.
Nabilone
The metabolism of Tamoxifen can be decreased when combined with Nabilone.
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Tamoxifen.
Naloxone
The metabolism of Naloxone can be decreased when combined with Tamoxifen.
Naproxen
The metabolism of Naproxen can be decreased when combined with Tamoxifen.
Nefazodone
The metabolism of Tamoxifen can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Tamoxifen can be decreased when combined with Nelfinavir.
Netupitant
The serum concentration of Tamoxifen can be increased when it is combined with Netupitant.
Nevirapine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Nevirapine resulting in a loss in efficacy.
Nicardipine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Nicardipine resulting in a loss in efficacy.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Tamoxifen.
Nicotine
The metabolism of Nicotine can be decreased when combined with Tamoxifen.
Nicotine Polacrilex
The metabolism of Nicotine can be decreased when combined with Tamoxifen.
Nilotinib
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Nilotinib resulting in a loss in efficacy.
Nintedanib
The serum concentration of Nintedanib can be decreased when it is combined with Tamoxifen.
Ofloxacin
Tamoxifen may increase the QTc-prolonging activities of Ofloxacin.
Olaparib
The metabolism of Tamoxifen can be decreased when combined with Olaparib.
Olodaterol
The metabolism of Olodaterol can be decreased when combined with Tamoxifen.
Ombitasvir
The metabolism of Ombitasvir can be decreased when combined with Tamoxifen.
Omeprazole
The metabolism of Tamoxifen can be decreased when combined with Omeprazole.
Ondansetron
Tamoxifen may increase the QTc-prolonging activities of Ondansetron.
Osimertinib
The serum concentration of Tamoxifen can be increased when it is combined with Osimertinib.
Ospemifene
The risk or severity of adverse effects can be increased when Tamoxifen is combined with Ospemifene.
Ouabain
Ouabain may decrease the cardiotoxic activities of Tamoxifen.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tamoxifen.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Tamoxifen.
Palbociclib
The serum concentration of Tamoxifen can be increased when it is combined with Palbociclib.
Paliperidone
Tamoxifen may increase the QTc-prolonging activities of Paliperidone.
Panobinostat
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Panobinostat resulting in a loss in efficacy.
Pantoprazole
The metabolism of Tamoxifen can be decreased when combined with Pantoprazole.
Paramethadione
The metabolism of Paramethadione can be decreased when combined with Tamoxifen.
Paregoric
The metabolism of Morphine can be decreased when combined with Tamoxifen.
Paroxetine
The serum concentration of Tamoxifen can be increased when it is combined with Paroxetine.
Pazopanib
The serum concentration of Pazopanib can be increased when it is combined with Tamoxifen.
Peginterferon Alfa-2b
The serum concentration of Tamoxifen can be decreased when it is combined with Peginterferon alfa-2b.
Pentamidine
The metabolism of Pentamidine can be decreased when combined with Tamoxifen.
Pentobarbital
The metabolism of Tamoxifen can be increased when combined with Pentobarbital.
Perflutren
Tamoxifen may increase the QTc-prolonging activities of Perflutren.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Tamoxifen.
Perphenazine
The metabolism of Perphenazine can be decreased when combined with Tamoxifen.
Phenindione
Tamoxifen may increase the anticoagulant activities of Phenindione.
Phenobarbital
The metabolism of Tamoxifen can be increased when combined with Phenobarbital.
Phenprocoumon
Tamoxifen may increase the anticoagulant activities of Phenprocoumon.
Phenytoin
The metabolism of Tamoxifen can be increased when combined with Phenytoin.
Pimozide
Tamoxifen may increase the QTc-prolonging activities of Pimozide.
Pioglitazone
The metabolism of Pioglitazone can be decreased when combined with Tamoxifen.
Piroxicam
The metabolism of Piroxicam can be decreased when combined with Tamoxifen.
Piroxicam-Beta-Cyclodextrin
The metabolism of Piroxicam can be decreased when combined with Tamoxifen.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Tamoxifen.
Ponatinib
The metabolism of Ponatinib can be decreased when combined with Tamoxifen.
Posaconazole
The metabolism of Tamoxifen can be decreased when combined with Posaconazole.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Tamoxifen.
Primaquine
Tamoxifen may increase the QTc-prolonging activities of Primaquine.
Primidone
The metabolism of Tamoxifen can be increased when combined with Primidone.
Procainamide
Tamoxifen may increase the QTc-prolonging activities of Procainamide.
Progesterone
The metabolism of Progesterone can be decreased when combined with Tamoxifen.
Promazine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Promazine resulting in a loss in efficacy.
Propafenone
Tamoxifen may increase the QTc-prolonging activities of Propafenone.
Propofol
The metabolism of Propofol can be decreased when combined with Tamoxifen.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Tamoxifen.
Pyrimethamine
The metabolism of Tamoxifen can be decreased when combined with Pyrimethamine.
Quazepam
The serum concentration of Tamoxifen can be increased when it is combined with Quazepam.
Quetiapine
Tamoxifen may increase the QTc-prolonging activities of Quetiapine.
Quetiapine fumarate
Tamoxifen may increase the QTc-prolonging activities of Quetiapine.
Quinidine
The serum concentration of Tamoxifen can be increased when it is combined with Quinidine.
Quinine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Quinine resulting in a loss in efficacy.
Ranolazine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ranolazine resulting in a loss in efficacy.
Repaglinide
The metabolism of Repaglinide can be decreased when combined with Tamoxifen.
Rifabutin
The metabolism of Tamoxifen can be increased when combined with Rifabutin.
Rifampin
The metabolism of Tamoxifen can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Tamoxifen can be increased when combined with Rifapentine.
Rifaximin
The metabolism of Tamoxifen can be increased when combined with Rifaximin.
Rilpivirine
The serum concentration of Rilpivirine can be decreased when it is combined with Tamoxifen.
Riociguat
The metabolism of Riociguat can be decreased when combined with Tamoxifen.
Ritonavir
The serum concentration of Tamoxifen can be increased when it is combined with Ritonavir.
Rofecoxib
The metabolism of Rofecoxib can be decreased when combined with Tamoxifen.
Rolapitant
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Rolapitant resulting in a loss in efficacy.
Ropinirole
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ropinirole resulting in a loss in efficacy.
Rosiglitazone
The metabolism of Rosiglitazone can be decreased when combined with Tamoxifen.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Tamoxifen.
Rucaparib
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Rucaparib resulting in a loss in efficacy.
Saquinavir
The metabolism of Tamoxifen can be decreased when combined with Saquinavir.
Saquinavir Mesylate
The metabolism of Tamoxifen can be decreased when combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Tamoxifen can be decreased when used in combination with Sarilumab.
Saxagliptin
The serum concentration of Saxagliptin can be decreased when it is combined with Tamoxifen.
Saxagliptin Anhydrous
The serum concentration of Saxagliptin can be decreased when it is combined with Tamoxifen.
Secobarbital
The metabolism of Tamoxifen can be increased when combined with Secobarbital.
Selegiline
The metabolism of Selegiline can be decreased when combined with Tamoxifen.
Selexipag
The metabolism of Selexipag can be decreased when combined with Tamoxifen.
Sertraline
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Sertraline resulting in a loss in efficacy.
Sildenafil
The metabolism of Tamoxifen can be decreased when combined with Sildenafil.
Silodosin
The serum concentration of Silodosin can be increased when it is combined with Tamoxifen.
Siltuximab
The serum concentration of Tamoxifen can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Tamoxifen can be increased when it is combined with Simeprevir.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Tamoxifen.
Sitagliptin
The metabolism of Sitagliptin can be decreased when combined with Tamoxifen.
Sitagliptin Phosphate
The metabolism of Sitagliptin can be decreased when combined with Tamoxifen.
Sofosbuvir
The serum concentration of Sofosbuvir can be decreased when it is combined with Tamoxifen.
Sorafenib
The metabolism of Tamoxifen can be decreased when combined with Sorafenib.
Sotalol
Tamoxifen may increase the QTc-prolonging activities of Sotalol.
ST. JOHN'S WORT EXTRACT
The serum concentration of Tamoxifen can be decreased when it is combined with St. John's Wort.
Sulfadiazine
The metabolism of Tamoxifen can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Tamoxifen can be decreased when combined with Sulfamethoxazole.
Sulfinpyrazone
The metabolism of Sulfinpyrazone can be decreased when combined with Tamoxifen.
Sulfisoxazole
The metabolism of Tamoxifen can be decreased when combined with Sulfisoxazole.
Tazarotene
The metabolism of Tazarotene can be decreased when combined with Tamoxifen.
Telaprevir
The metabolism of Tamoxifen can be decreased when combined with Telaprevir.
Telavancin
Tamoxifen may increase the QTc-prolonging activities of Telavancin.
Telithromycin
The metabolism of Tamoxifen can be decreased when combined with Telithromycin.
Temazepam
The metabolism of Temazepam can be decreased when combined with Tamoxifen.
Tenofovir Disoproxil
The metabolism of Tamoxifen can be decreased when combined with Tenofovir disoproxil.
Terbinafine
The serum concentration of Tamoxifen can be increased when it is combined with Terbinafine.
Teriflunomide
The serum concentration of Tamoxifen can be decreased when it is combined with Teriflunomide.
Testosterone
The metabolism of Testosterone can be decreased when combined with Tamoxifen.
Testosterone Cypionate
The metabolism of Testosterone cypionate can be decreased when combined with Tamoxifen.
Testosterone Enanthate
The metabolism of Testosterone enanthate can be decreased when combined with Tamoxifen.
Testosterone Undecanoate
The metabolism of Testosterone undecanoate can be decreased when combined with Tamoxifen.
Tetrabenazine
Tamoxifen may increase the QTc-prolonging activities of Tetrabenazine.
Theophylline
The metabolism of Tamoxifen can be decreased when combined with Theophylline.
Theophylline anhydrous
The metabolism of Tamoxifen can be decreased when combined with Theophylline.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Tamoxifen.
Thiotepa
The metabolism of Tamoxifen can be decreased when combined with Thiotepa.
Ticagrelor
The metabolism of Tamoxifen can be decreased when combined with Ticagrelor.
Ticlopidine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ticlopidine resulting in a loss in efficacy.
Tipranavir
The serum concentration of Tamoxifen can be increased when it is combined with Tipranavir.
Tocilizumab
The serum concentration of Tamoxifen can be decreased when it is combined with Tocilizumab.
Tolbutamide
The metabolism of Tamoxifen can be decreased when combined with Tolbutamide.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Tamoxifen.
Topiramate
The metabolism of Tamoxifen can be decreased when combined with Topiramate.
Topotecan
The serum concentration of Topotecan can be increased when it is combined with Tamoxifen.
Toremifene
Tamoxifen may increase the QTc-prolonging activities of Toremifene.
Torsemide
The metabolism of Torasemide can be decreased when combined with Tamoxifen.
Tranylcypromine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Tranylcypromine resulting in a loss in efficacy.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Tamoxifen.
Tretinoin
The metabolism of Tretinoin can be decreased when combined with Tamoxifen.
Trimethadione
The metabolism of Trimethadione can be decreased when combined with Tamoxifen.
Trimethoprim
The metabolism of Tamoxifen can be decreased when combined with Trimethoprim.
Troglitazone
The metabolism of Troglitazone can be decreased when combined with Tamoxifen.
Valproate
The metabolism of Tamoxifen can be decreased when combined with Valproic Acid.
Valproic Acid
The metabolism of Tamoxifen can be decreased when combined with Valproic Acid.
Valsartan
The metabolism of Tamoxifen can be decreased when combined with Valsartan.
Vandetanib
Tamoxifen may increase the QTc-prolonging activities of Vandetanib.
Velpatasvir
The metabolism of Velpatasvir can be decreased when combined with Tamoxifen.
Vemurafenib
The serum concentration of Tamoxifen can be increased when it is combined with Vemurafenib.
Venlafaxine
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Venlafaxine resulting in a loss in efficacy.
Verapamil
The metabolism of Tamoxifen can be decreased when combined with Verapamil.
Vincristine
The serum concentration of Vincristine can be decreased when it is combined with Tamoxifen.
Voriconazole
The metabolism of Tamoxifen can be decreased when combined with Voriconazole.
Vortioxetine
The metabolism of Vortioxetine can be decreased when combined with Tamoxifen.
Voxilaprevir
The metabolism of Voxilaprevir can be decreased when combined with Tamoxifen.
Warfarin
Tamoxifen may increase the anticoagulant activities of Warfarin.
Zafirlukast
The metabolism of Tamoxifen can be decreased when combined with Zafirlukast.
Zidovudine
The metabolism of Zidovudine can be decreased when combined with Tamoxifen.
Ziprasidone
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ziprasidone resulting in a loss in efficacy.
Zopiclone
The metabolism of Zopiclone can be decreased when combined with Tamoxifen.
Zuclopenthixol
Tamoxifen may increase the QTc-prolonging activities of Zuclopenthixol.
